References
- González A , ContrerasL, AngelesAet al. Pharmacokinetics of diphenylboroxazolidones of l-α-amino acids with activity on the CNS: quantification in rat DBS by UPLC–MS/MS. Bioanalysis3(4), 439–448 (2011).
- Li W , TseFL. Dried blood spot sampling in combination with LC–MS/MS for quantitative analysis of small molecules. Biomed. Chromatogr.24(1), 49–65 (2010).
- Timmerman P , WhiteS, CobbZet al. Update of the EBF recommendation for the use of DBS in the regulated bioanalysis integrating the conclusions from the EBF DBS Microsampling Consortium. Bioanalysis5(17), 2129–2136 (2013).
- Contreras L , RiveraL, MorenoAet al. Development of a UPLC–MS/MS method for the quantification of sildenafil by DBS, and its use on pediatric pulmonary hypertension. Bioanalysis6(21), 2815–2824 (2014).
- Norma Oficial Mexicana NOM-004- ZOO-1999. Control of toxic residues in meat, fat, liver and kidney of bovines, equines, porcines and ovines. SAGARPA, Mexico (1999). http://www.porcimex.org/NORMAS/NOM-004-ZOO-1994.pdf
- Mexican Pharmacopeia. Farmacopea de los Estados Unidos Mexicanos. Secretaría de Salud. Métodos Generales de Análisis (2019). https://www.farmacopea.org.mx/
- Norma Oficial Mexicana NOM-177-SSA1-2013. Guidelines to establish bioequivalence between test and reference formulations. Guidelines to establish biocomparability between biotech products. http://www.dof.gob.mx/nota_detalle.php?codigo=5314833&fecha=20/09/2013
- National Register of Clinical Assays in Mexico (RNEC-COFEPRIS). http://siipris03.cofepris.gob.mx/Resoluciones/Consultas/ConWebRegEnsayosClinicos.asp
- Woolf E , McDougallS, FastDet al. Small molecule specific run acceptance, specific assay operation, and chromatographic run quality assessment: recommendation for best practices and harmonization from the Global Bioanalysis Consortium harmonization teams. AAPS J.16(5), 885–892 (2014).
- Marcelín-Jiménez G . How pitfalls during drug quantitation by mass spectrometry may affect the variability of pharmacokinetic data during a bioequivalence trial. J. Bioequiv. Availab.9(4), 430–431 (2017).
- Peñaloza C , MarcelínJG, LópezMet al. Development of memantine orodispersible tablets and their in vitro description and biopharmaceutical performance. Int. J. Pharmacokinet.3(1), 13–21 (2018).